EGFR and non-small cell lung carcinoma: It has been proved that three major epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs - gefitinib, erlotinib and afatinib) were the best choice for advanced chemo-naïve non-small cell lung cancer (NSCLC) patients harboring sensitive EGFR mutations from nine phase III, randomized trials.